Patents by Inventor Suresh Borsadia
Suresh Borsadia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230364030Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.Type: ApplicationFiled: July 21, 2023Publication date: November 16, 2023Applicant: Shinkei Therapeutics, Inc.Inventors: Gurpartap Singh Sachdeva, Suresh Borsadia, Kalpana Patel, Krunal Raval
-
Patent number: 11707439Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.Type: GrantFiled: April 6, 2020Date of Patent: July 25, 2023Assignee: Shinkei Therapeutics, Inc.Inventors: Gurpartap Singh Sachdeva, Suresh Borsadia, Kalpana Patel, Krunal Raval
-
Publication number: 20230082617Abstract: The invention relates to a dosing regimen for administering a liquid pharmaceutical composition of amantadine hydrochloride to a patient having a traumatic brain injury. The dosing regimen includes administering a first dose and administering a second dose of amantadine hydrochloride. The step of administering a first dose is by an intravenous route and the first dose comprises between 100 mg and 200 mg of amantadine hydrochloride in an aqueous solution of about 200 ml to about 300 ml over a period of about two to about four hours. The step of administering a second dose is by an intravenous route and the first dose comprises between 100 mg and 200 mg of amantadine hydrochloride in an aqueous solution of about 200 ml to about 300 ml over a period of about two to about four hours. The second dose is administered after at least about four to at least about six hours after the completion of administration of the first dose.Type: ApplicationFiled: October 26, 2022Publication date: March 16, 2023Inventors: Krunal Raval, Suresh Borsadia, Kalpana Patel
-
Publication number: 20220401383Abstract: Compositions comprising cannabidiol and one or more compounds which are inhibitors of CYP2C19 and CYP3A4 enzymes are disclosed. Methods of treating pain, epilepsy, sleep deprivation, vomiting, nausea, psychosis, anxiety, depression, movement disorders, and other neuropsychiatric or neurogenic diseases using such compositions are also provided. Compositions comprising cobicistat, or pharmaceutically acceptable isomers, salts, and/or solvates thereof; and at least one therapeutic agent which is metabolized by CYP2C19, and optionally CYP3A4, are provided. Methods for inhibiting CYP2C19, and optionally CYP3A4, in a patient in need thereof are also provided, comprising administering to the patient an amount of cobicistat, or pharmaceutically acceptable isomers, salts, and/or solvates thereof, effective for inhibiting CYP2C19, and optionally CYP3A4, in the patient.Type: ApplicationFiled: November 23, 2020Publication date: December 22, 2022Inventors: Suresh Borsadia, Kalpana Patel, Krunal RAVAL
-
Publication number: 20220362165Abstract: Provided herein are compositions, delivery devices, and methods relating to the delivery of tetrabenazine and/or deuterated tetrabenazine, for example, continuous or substantially continuous delivery such as transdermal delivery, for the treatment of a hyperkinetic movement disorder. Also provided are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, pharmaceutical compositions comprising tetrabenazine and/or a deuterated tetrabenazine, methods of preparing the same, and methods of using the same for example, for the treatment of a hyperkinetic movement disorder.Type: ApplicationFiled: October 21, 2020Publication date: November 17, 2022Inventors: Krunal RAVAL, Suresh BORSADIA, Hock S. TAN, Kalpana PATEL
-
Publication number: 20220331264Abstract: Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.Type: ApplicationFiled: July 6, 2022Publication date: October 20, 2022Inventor: Suresh BORSADIA
-
Patent number: 11382869Abstract: Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.Type: GrantFiled: October 3, 2018Date of Patent: July 12, 2022Assignee: SHINKEI THERAPEUTICS LLCInventor: Suresh Borsadia
-
Publication number: 20210128490Abstract: Provided herein are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof. Also provided herein are pharmaceutical compositions, such as adhesive compositions, comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, for example, homogenously dispersed in an adhesive, such as a pressure sensitive adhesive. Further provided herein are methods of using the transdermal delivery devices or pharmaceutical compositions, for example, for treating a hyperkinetic movement disorder.Type: ApplicationFiled: April 24, 2019Publication date: May 6, 2021Inventors: Suresh BORSADIA, Kalpana PATEL, Hock S. TAN
-
Publication number: 20200323788Abstract: Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.Type: ApplicationFiled: October 3, 2018Publication date: October 15, 2020Inventor: Suresh BORSADIA
-
Publication number: 20200315991Abstract: A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.Type: ApplicationFiled: April 6, 2020Publication date: October 8, 2020Inventors: Gurparatap Singh Sachdeva, Suresh Borsadia, Kalpana Patel, Krunal Raval
-
Patent number: 8246981Abstract: Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive.Type: GrantFiled: November 10, 2006Date of Patent: August 21, 2012Assignee: Abeille Pharamaceuticals, Inc.Inventors: Kalpana J Patel, Suresh Borsadia
-
Publication number: 20100158990Abstract: A method of treating an individual having a disease or for diagnostic purposes requiring administration of a corticosteroid, which involves applying to a portion of intact derma on the individual a transdermal patch having a backing layer and a matrix adhesive layer. The matrix adhesive layer includes a skin-compatible pressure-sensitive adhesive, a corticosteroid, and at least one permeation enhancer. The matrix adhesive layer, when applied to the skin of the individual, transdermally and continuously delivers the corticosteroid to the mammal for systemic treatment of the disease or for the diagnostic purpose.Type: ApplicationFiled: December 26, 2007Publication date: June 24, 2010Applicant: ABIELLE PHARMACEUTICALS, INCInventors: Suresh Borsadia, Kalpana Patel
-
Publication number: 20070098778Abstract: Provided, among other things, is a formulation or kit comprising: (a) a pharmaceutically effective dosage of one or more a glucose-level-controlling bioactive agents selected from an ?-glucodase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPAR?/? agonist, PPAR? agonist or insulin secretagogue; and (b) a pharmaceutically effective dosage of (i) one or more of an antihypertensive bioactive agent selected from an ACE inhibitor, calcium channel blocker, beta blocker, angiotension II receptor antagonist or diuretic, or (ii) one or more of an anti-dyslipidemia bioactive agent selected from a HMG-CoA reductase inhibitor, bile acid sequestrant, fibric acid derivative, sterol, cholesterol absorption inhibitor, MTP inhibitor or nicotinic acid derivative; wherein: in the case of (i) a combination of a first bioactive agent of group (a) that is metformin with a second bioactive agent of group (b), or (ii) a combination of a first bioactive agent of group (a) that is a thiazolidinediType: ApplicationFiled: February 28, 2005Publication date: May 3, 2007Applicant: ABEILLE PHARMACEUTICALS, INC.Inventor: Suresh Borsadia
-
Publication number: 20070087044Abstract: Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive.Type: ApplicationFiled: November 10, 2006Publication date: April 19, 2007Applicant: ABEILLE PHARMACEUTICALS, INC.Inventors: Kalpana Patel, Suresh Borsadia
-
Publication number: 20060263421Abstract: Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive, wherein a plasma concentration of the 5-HT3 receptor antagonist in a therapeutically effective range is provided for period of time from an onset time to 12 hours or more after the composition is removed.Type: ApplicationFiled: April 26, 2006Publication date: November 23, 2006Applicant: Abeille Pharmaceuticals IncInventors: Kalpana Patel, Suresh Borsadia
-
Patent number: 5774446Abstract: The present invention relates to a segmented cylindrical audio-visual device (10) having interlocking disks (12) a first disk (12A) has a first disk bottom side (12AB) with a first disk bottom side female connector (12ABB) centrally positioned thereon. The adjacent second disk (12B) has a second disk top side (12BA) with a second disk top side male connector (12BAB) centrally positioned thereon. The second disk top side male connector (12BAB) is complimentary to and inserts into the first disk bottom side female connector (12ABB) thereby interlocking the first disk (12A) to the adjacent second disk (12B). Each interlocked disk (12) has a disk side (12AC . . . 12JC) having a respective disk side audio-visual track (12ACA . . . 12JCA) thereon. The respective disk side audio-visual tracks (12ACA . . . 12JCA) each represent a separate audio and/or visual track analogous to a song and a music video, respectively.Type: GrantFiled: December 27, 1995Date of Patent: June 30, 1998Inventor: Suresh Borsadia
-
Patent number: 5626866Abstract: A method for making a transdermal drug delivery device for heat sensitive and volatile drugs is disclosed. The device contains a drug-containing adhesive composite layer having an impermeable backing material laminated to the distal surface thereof and a proximal peelable impermeable backing material adapted for removal for administering a drug to the skin or mucosa laminated to the proximal surface thereof. The method comprising the steps of providing first and second adhesive laminates each comprising a drug permeable adhesive layer having laminated to one surface one of said backing materials and having the opposing surface exposed.Type: GrantFiled: October 17, 1995Date of Patent: May 6, 1997Assignee: Theratech, Inc.Inventors: Charles D. Ebert, Srinivasan Venkateshwaran, Werner Heiber, Suresh Borsadia